Lyell Immunopharma (LYEL)
(Real Time Quote from BATS)
$1.46 USD
-0.03 (-2.01%)
Updated Aug 5, 2024 02:56 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Industry / Sector Report
Industry : Medical - Drugs
Zacks Industry Rank
Bottom 39% (154 out of 251)Zacks Sector Rank
Top 25% (4 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 2.60 | 1.52 | 9.99 |
Current Quarter Estimate | -0.20 | -2.04 | 61.00 |
Year Ago Quarter Estimate | -0.26 | -0.59 | 54.84 |
Next Quarter Estimate | -0.20 | -2.00 | 63.00 |
Next Year Estimate | -0.91 | 6.92 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 8.60 | 14.00 | 15.67 |
Next Year | -7.06 | 16.30 | 11.34 |
Last 5 Years | NA | 7.00 | 8.10 |
Next 5 Years | NA | 24.90 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -5.88 |
Price/Book (MRQ) | 0.63 | 1.84 |
Price/Cash Flow (MRFY) | NA | 8.95 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -335,794.09% | -13.40% |
Return on Equity (TTM) | -33.92% | -71.77% |
Debt to Equity (MRQ) | NA | 0.04 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.